Patient-derived teratomas as a humanized platform for dystrophin restoration by ex vivo cell therapy and in vivo base editing
Open Access
- 1 October 2026
- journal article
- research article
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (10) , 3370-3381
Abstract
Cell and gene therapies hold great promise for treating monogenic disorders, yet their preclinical evaluation remains limited by the lack of scalable, human-specific models. Here we establish a patient-derived teratoma xenograft platform as a proof-of-concept system to evaluate ex vivo and in vivo therapeutic strategies for Duchenne muscular dystrophy (DMD). Teratomas generated from DMD patient-derived induced pluripotent stem cells contained mesodermal derivatives, including skeletal muscle-like tissue, enabling assessment of dystrophin restoration after therapeutic intervention. For ex vivo cell therapy, myogenic progenitors derived from adenine base editor-corrected induced pluripotent stem cells were transplanted into DMD teratomas, resulting in partial restoration of shorter dystrophin isoforms but not reproducible recovery of full-length Dp427m. For in vivo gene editing, local delivery of adenine base editor mRNA encapsulated in lipid nanoparticles induced dose-dependent editing and restoration of shorter dystrophin isoforms, including Dp71. Full-length, muscle-specific Dp427m was detected only in a subset of sequentially matured secondary teratomas with enriched muscle differentiation, indicating that myogenic maturation is a critical determinant of this therapeutic readout. Together, these findings support patient-derived DMD teratomas as an exploratory humanized platform for evaluating patient-specific gene correction and dystrophin isoform restoration, while highlighting the need for further optimization to reproducibly model full-length Dp427m recovery.Keywords
Funding Information
- Korean Ministry of Science and ICT
This publication has 48 references indexed in Scilit:
- Optimized genomic editing of a common Duchenne muscular dystrophy mutation in patient-derived muscle cells and a new humanized mouse modelMolecular Therapy Nucleic Acids, 2025
- Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancersCell Reports, 2023
- Lethal immunotoxicity in high-dose systemic AAV therapyMolecular Therapy, 2023
- A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editingMolecular Therapy Nucleic Acids, 2022
- Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal modelMolecular Therapy, 2022
- Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophyMolecular Therapy, 2021
- Defining the Teratoma as a Model for Multi-lineage Human DevelopmentCell, 2020
- Delivering the Messenger: Advances in Technologies for Therapeutic mRNA DeliveryMolecular Therapy, 2019
- Skeletal Muscle Stem Cells from PSC-Derived Teratomas Have Functional Regenerative CapacityCell Stem Cell, 2018
- Dystrophin in skeletal muscle I. Western blot analysis using a monoclonal antibodyJournal of the Neurological Sciences, 1989